The large array of different glycolipids described in mammalian tissues is a reflection, in part, of diverse glycosyltransferase expression. Herein, we describe the cloning of a UDP-galactose: ␤-D-galactosyl-1,4-glucosylceramide ␣-1,3-galactosyltransferase (iGb 3 synthase) from a rat placental cDNA expression library. iGb 3 synthase acts on lactosylceramide, LacCer (Gal␤1,4Glc-␤1Cer) to form iGb 3 (Gal␣1,3Gal␤1,4Glc␤1Cer) initiating the synthesis of the isoglobo-series of glycosphingolipids. The isolated cDNA encoded a predicted protein of 339 amino acids, which shows extensive homology (40 -50% identity) to members of the ABO gene family that includes: murine ␣1,3-galactosyltransferase, Forssman (Gb 5 ) synthase, and the ABO glycosyltransferases. In contrast to the murine ␣1,3-galactosyltransferase, iGb 3 synthase preferentially modifies glycolipids over glycoprotein substrates. Reverse transcriptase-polymerase chain reaction revealed a widespread tissue distribution of iGb 3 synthase RNA expression, with high levels observed in spleen, thymus, and skeletal muscle. As an indirect consequence of the expression cloning strategy used, we have been able to identify several potential glycolipid biosynthetic pathways where iGb 3 functions, including the globo-and isoglobo-series of glycolipids.
There are many diverse glycans found in nature that may be synthesized on different aglycone substrates, including proteins and lipids. The glycosphingolipids (GSL) 1 are organized, based on their carbohydrate structure, into six major series in vertebrates: gangliosides, lacto-, neolacto-, muco-, isoglobo-, and globo-series GSL (1) . The common precursor to these GSL is LacCer (Gal␤1,4Glc␤1Cer). Recently, the vital importance of GSL has been demonstrated through the null mutation of glucosylceramide synthase (2) , the first step in the synthesis of the majority of GSL. The significance of individual glycan structures within the major GSL series arising from LacCer remains to be established. To date, animals deficient in glycosyltransferases involved in the terminal modifications have not yielded the prominent or lethal phenotypes associated with the loss of the ability to synthesize core regions of glycans. Targeting null mutations in glycosyltransferases acting at key branch points in GSL biosynthesis will help reveal the contributions of the different series of GSL. As a first step to this approach we have cloned Gb 3 synthase and iGb 3 synthase, two transferases that act on LacCer and initiate the synthesis of the globo-and isoglobo-series of GSL. Following the synthesis of Gb 3 (Gal␣1,4Gal␤1,4Glc␤1Cer) or iGb 3 (Gal␣1,3Gal␤1,4Glc␤1Cer) (boldface is used to show the linkage of saccharide transferred by Gb 3 synthase and/or iGb 3 synthase), sequential addition of GalNAc residues by Gb 4 synthase and Gb 5 synthase leads to the production of both Gb 4 and Gb 5 or iGb 4 and iGb 5 , respectively. Using a mAb SMLDN1.1 that detects GalNAc on these downstream products, we have cloned Gb 3 and iGb 3 synthases from a rat placental cDNA expression library. In this paper we described the cloning of iGb 3 synthase, an ␣1,3-galactosyltransferase, that shares high homology with other glycosyltransferases in the histo-blood group ABO gene family but differs in its substrate specificity.
EXPERIMENTAL PROCEDURES
Rat Placental cDNA Library-RNA was isolated from normal rat placental tissue, gestation day 18, and used to prepare a cDNA library with the mammalian expression vector pCDM8. This cDNA library, RPL18, was generously provided by Dr. P. Smith, University of Michigan.
Cell Culture-Chinese hamster ovary (CHO) cells were grown in Ham's F-12 medium with 10% fetal bovine serum Ϯ 2 M 1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol, HCl (DL-threo-PPPP, Calbiochem, CA), an inhibitor of glucosylceramide synthase (3) .
SMLDN1.1 mAb Binding Specificity-The generation and characterization of this SMLDN1.1 mAb has been described previously (4) . Subsequent analysis of SMLDN1.1 binding characteristics with additional carbohydrate structures indicates that the presence of a single terminal * This work was supported by National Institutes of Health Grant R01-DK 41738 (to J. U. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The 1 The abbreviations for the glycosphingolipids are in accordance with the 1997 recommendations of the IUPAC-IUB Joint Commission of Biochemical Nomenclature. The abbreviations used are: GSL, glycosphingolipid; LacCer, lactosylceramide (Gal␤1,4Glc␤1Cer); Cer, ceramide; Gal, galactose; GalNAc, N-acetylgalactosamine; Glc, glucose; Gb 3 , P k , CD77 or globotriaosylceramide (Gal␣1,4Gal␤1,4Glc␤1Cer); iGb 3 , isoglobotriaosylceramide (Gal␣1,3Gal␤1,4Glc␤1Cer); Gb 4 , globoside (GalNAc␤1,3Gal␣1,4Gal␤1,4Glc␤1Cer); iGb 4 , isogloboside (GalNAc␤1, 3Gal␣1,3Gal␤1,4Glc␤1Cer); Gb 5 , Forssman (GalNAc␣1,3GalNAc␤1, 3Gal␣1,4Gal␤1,4Glc␤1Cer); iGb 5 , isoForssman (GalNAc␣1,3GalNAc-␤1,3Gal␣1,3Gal␤1,4Glc␤1Cer); G M3 , Neu5Ac␣2,3Gal␤1,4Alc␤1Cer; mAb, monoclonal antibody; PPPP, 1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol, hydrochloride; TLC, thin layer chromatography; FACS, fluorescence-activated cell sorting; RT-PCR, reverse transcriptase-polymerase chain reaction; PBS, phosphate-buffered saline; BSA, bovine serum albumin; FITC, fluorescein isothiocyanate; MES, 2-(N-morpholino)ethane sulfonic acid; HPLC, high performance liquid chromatography; Neu5Ac, sialic acid.
GalNAc residue in either an ␣ or ␤ linkage is sufficient for recognition. We have observed that SMLDN1.1 mAb efficiently recognizes the terminal GalNAc residues in both Gb 4 (GalNAc␤1,3) and Gb 5 (GalNAc␣1,3GalNAc␤1,3).
Expression Cloning of a Rat iGb 3 Synthase cDNA-RPL18 plasmid cDNA was isolated from an overnight culture of transformed Escherichia coli MC1061/P3 cells selected in 50 g/ml ampicillin and 10 g/ml tetracycline. Ten 100-mm plates of CHO cells (2.5 ϫ 10 6 cells per plate) were cotransfected with 10 g of RPL18 plasmid cDNA and 3 g of pSVE1-PyE plasmid, harboring the polyoma large T cDNA (a kind gift from Dr. Minoru Fukuda, The Burnham Institute), using Lipofectamine (Life Technologies, Inc.). The pCDM8 vector requires the polyoma large T antigen for high levels of replication, but unlike the library vector the pSVE1-PyE plasmid is neither amplified nor selected in subsequent enrichment steps, because it lacks the supF gene (5). Cells were harvested using 0.02% EDTA 60 h post-transfection, stained with SMLDN1.1 mAb, and processed for flow cytometry (FACS). Plasmid cDNA was recovered, from the FACS-sorted cells, by Hirt extraction (6) and amplified in E. coli MC1061/P3. Two further rounds of transfection and FACS enrichment were performed. Plasmid cDNA obtained from the third FACS sort was transformed into E. coli MC1061/P3, and dilutions were plated. Plaque lifts from these dilution plates were used to prepare more plasmid cDNA for transfection into CHO cells and screened with the SMLDN1.1 mAb via FACS. A positive plate with 590 colonies was divided into 12 smaller pools of 50 colonies, which were subsequently screened for SMLDN1.1 binding. This process was repeated on the reactive smaller pool until a single plasmid was isolated whose expression in CHO cells conferred reactivity with SMLDN1.1 mAb. We refer to this cDNA clone as iGb 3 synthase.
DNA Sequencing-Plasmid cDNA was isolated from clones of interest using Qiagen columns. The cDNA insert was sequenced using T7, a pCDM8 reverse primer and gene-specific primers, in a reaction mix containing ABI Big-Dye terminators with AmpliTaq DNA polymerase according to the manufacturer's instructions (PE Applied Biosystems). Reaction products were run on an ABI 310 sequencer. Complete insert sequence was obtained in both directions and compared against sequences held in GenBank using BLAST (NCBI). Additional analysis was performed using Geneworks (version 2.5, Oxford Molecular, UK) and the transmembrane prediction program TMHMM (7) .
Site Assay of ␣1,3GalT Activity-Cell extracts from transfected CHO cells were prepared and assayed as described previously except 100 mM sodium cacodylate, pH 6.8 was used in place of MES buffer (8) . Supernatants from the cultured cells were concentrated 10-fold, using Microcon-10 (Millipore) mini-spin columns, prior to assaying a 50-l fraction. The reaction mixture contained the following in a final volume of 100 l: 100 mM sodium cacodylate-HCl, pH 6.8, 0.5% Triton X-100, 5 mM ATP, protease inhibitors (50 g/ml turkey egg white trypsin inhibitor, 20 g/ml leupeptin, 20 g/ml antipain, 20 g/ml pepstatin, 20 g/ml chymotrypsin, and 0.115 trypsin inhibitor units/ml aprotinin, Sigma), 250 M UDP-galactose, UDP-[
3 H]galactose (800 cpm/pmol) (American Radiolabeled Chemicals, Inc.), 15 mM MnCl 2 , 1 mM LacCer (Sigma). Reactions were started with the addition of 15-or 50-g membrane fractions or 50 l of concentrated culture supernatant and incubated for 90 min or overnight at 37°C. The enzyme assay was linear over these times. Reaction products were isolated by reverse-phase chromatography using Sep-Pak C 18 cartridges (Waters, MA) and analyzed by thin layer chromatography (TLC) using silica gel aluminum-backed plates (Whatman) developed in chloroform:methanol:water (65:25:4, v/v). After drying, the plates were sprayed with En 3 Hance (NEN Life Science Products) then exposed to Kodak BioMax MR x-ray film at Ϫ80°C. Neutral glycolipid standards from porcine blood (Calbiochem) were included, and this portion of the plate was cut-off and sprayed with orcinol.
Metabolic Labeling of CHO Cells-The day after transfection, cells were labeled with either 35 Ci/ml [ 3 H]Gal or [ 3 H]GlcNAc (NEN Life Science Products) for a further 24 -48 h. Cells were scraped off the culture plate, and glycolipids were extracted in chloroform/methanol as described previously (8) .
Glycolipid Digestion with Exoglycosidases-Glycolipid extracts (approximately 1-10 g or 30,000 cpm) were isolated over a Sep-Pak C 18 cartridge and separated by HPLC using an Iatrobead column (kindly provided by Dr. R. Schnaar, John Hopkins School of Medicine) as described (9) . Pooled peak fractions were digested overnight at 37°C with exoglycosidases in the presence of 0.05% sodium taurodeoxycholate in a final volume of 10 l. The glycosidases used included ␣-galactosidase (green coffee bean, Calbiochem); ␣1,3-galactosidase (recombinant Escherichia coli, Calbiochem); ␤1,3,4,6-galactosidase (bovine testes, Calbiochem); ␣-N-acetylgalactosaminidase (chicken liver, Oxford GlycoSciences, UK); and ␤-N-acetylhexosaminidase (Streptomyces plicatus recombinant in E. coli, New England BioLabs). The digested samples were re-isolated using a Sep-Pak C 18 cartridge prior to separation on TLC as described above.
Expression of iGb 3 Synthase in Rat Tissues Using RT-PCR-Tissues were taken from a 6-month-old female Long Evans rat and snap-frozen in liquid nitrogen. These tissues were homogenized in Trizol (Life Technologies), and total RNA was purified according to the manufacturer's instructions. The quality and quantity of RNA was verified by gel electrophoresis. First strand cDNA synthesis was prepared from 1-5 g of RNA using the reverse transcriptase enzyme, Superscript II, and oligo(dT) primer (Life Technologies). Gene-specific primer pairs were used in the PCR to yield an expected product size of 780 base pairs. Glyceraldehyde-3-phosphate dehydrogenase gene-specific primers were used as a control. Products were analyzed by gel electrophoresis. 3 Synthase cDNA Clone-Phenotypic cloning has been used to isolate many glycosyltransferase genes, which are typically expressed at low levels in cells (10) . The screening strategy used in this paper relies on the specificity of the SMLDN mAb, which recognizes terminal GalNAc residues. Positive clones identified in this cloning approach are involved in the cell surface expression of a GalNAc epitope. Despite expecting the isolated clone to express GalNAc transferase activity, no such activity was detected. These results were initially confusing until it became apparent that our readout signal, GalNAc expression, was in fact the product of a key upstream biosynthetic step. Thus, the isolated clone synthesizes iGb 3 , a product that Gb 4 and Gb 5 synthases, enzymes endogenous to the CHO host recipient cells, convert to iGb 4 and iGb 5 , respectively. Using this expression cloning procedure, the iGb 3 synthase cDNA (accession number AF248543) and later Gb 3 synthase cDNA (accession number AF248544, see Keusch et al., companion paper (35)) were isolated from the rat placental library, RPL18.
RESULTS

Isolation of a Rat iGb
cDNA Sequence Analysis-Sequencing of the iGb 3 synthase cDNA clone revealed an insert of 1496 base pairs. Translation from the first methionine in the open reading frame predicts a protein of 339 amino acids (Fig. 1) . The TMHMM transmembrane prediction program (7) identifies a single transmembrane domain of 19 amino acids with a type II transmembrane topology typical of Golgi glycosyltransferases (11) . Other hydrophobic regions are also apparent, including two stretches near the N terminus (residues 15-29 and 34 -58) but are not predicted to be membrane spanning by the TMHMM program. Two N-linked glycosylation consensus sequences are present in the stem region. Within the putative catalytic domain there is a 198 DVD 200 sequence. Mutation of the DXD motif in other glycosyltransferases results in the loss of enzyme activity (12) .
iGb 3 Synthase Belongs to the Histo-blood Group ABO Gene Family-BLAST (NCBI) sequence analysis identified significant homology (39% identity) at the amino acid level between iGb 3 synthase and members of the ABO glycosyltransferases, including ␣1,3-galactosyltransferase (␣1,3GalT), Forssman (Gb 5 ) synthase, and blood group A and B synthases (Fig. 2) . The identity is as high as 51% in the putative catalytic domain with three conserved cysteines and the DXD motif. All members of this gene family catalyze the transfer of a UDP-sugar in Expression Cloning of iGb 3 Synthasean ␣1,3-linkage to a ␤-linked Gal/GalNAc. iGb 3 synthase represents the third distinct ␣1,3-galactosyltransferase in the ABO gene family.
Expression of iGb 3 Synthase in CHO Cells Leads to the Synthesis of the Isoglobo-series GSL-FACS analysis shows that CHO cells transfected with iGb 3 synthase cDNA express high levels of terminal GalNAc on their cell surface. In contrast, CHO cells transfected with the pCDM8 vector did not express terminal GalNAc. The highest reactivity in the iGb 3 synthase cDNA transfectants is seen using the SMLDN1.1 mAb, with approximately 70% of the transfected cells expressing terminal GalNAc (Fig. 3) . This positive staining is predominantly due to glycolipids, because reactivity to the SMLDN1.1 mAb is lost when transfectants are cultured in the presence of PPPP, an inhibitor of the major series of GSL (3). Apart from G M3 , parent CHO cells do not synthesize any GSL beyond LacCer (13) . Therefore, we were surprised to see that transfection of iGb 3 synthase cDNA into CHO cells results in strong reactivity with the anti-Forssman (Gb 5 ) glycolipid mAb (Fig. 3) . Forssman glycolipid, Gb 5 (GalNAc␣1,3GalNAc␤1,3Gal␣1,4Gal␤1,4Glc␤-1Cer), and iGb 5 (GalNAc␣1,3GalNAc␤1,3Gal␣1,3Gal␤1, 4Glc␤1Cer), represent the terminal structures in the globo-and isoglobo-series GSL, respectively (14, 15) . Transfection of Gb 5 synthase cDNA into parent CHO cells does not result in Gb 5 or iGb 5 expression due to the absence of precursor substrates (35) . Therefore, we reasoned that the iGb 3 synthase cDNA is able to initiate the synthesis of isoglobo-GSL in CHO cells. Gb 4 synthase and Gb 5 synthase but not Gb 3 synthase nor iGb 3 synthase are endogenous to CHO cells. Thus, the de novo production of iGb 3 in CHO cells, transfected with the iGb 3 synthase cDNA, provides substrate for the sequential addition of ␤1,3-and ␣1,3GalNAc moieties by Gb 4 and Gb 5 synthases, respectively. Assuming similar expression levels, a catalytically inactive form of iGb 3 3 synthase cDNA were cultured in the absence (thick line) or presence of PPPP (thin line) and stained for surface expression of terminal carbohydrates on GSL: GalNAc (SMLDN1.1 mAb); Gal␣1,3Gal (G. simplicifolia lectin I-B 4 -biotin); Gb 5 (GalNAc␣1,3GalNAc␤1,3Gal␣1,4Gal␤1,4Glc␤1Cer) using anti-Gb 5 (Forssman) glycolipid M1/22.21 mAb; or Gb 3 (Gal␣1,4Gal␤1,4Glc␤1Cer) using anti-CD77 mAb clone 38-13 prior to analysis by FACS. Control primary antibodies are shown using a dotted line. Secondary reagents included anti-IgM-FITC and streptavidin-FITC.
synthase cDNA results in the synthesis of isoglobo-GSL but not globo-GSL (Gb 3 core structures) as indicated by the lack of reactivity with anti-CD77/Gb 3 (Gal␣1,4Gal␤1,4Glc␤1Cer) (Fig.  3) or anti-SSEA-3 (Gal␤1,3GalNAc␤1,3Gal␣1,4Gal␤1,4Glc␤-1Cer) mAbs (data not shown).
Extensive homology seen between iGb 3 synthase and a previously cloned murine ␣1,3GalT prompted us to compare their ability to synthesize isoglobo-GSL. CHO cells transfected with either ␣1,3GalT cDNA or iGb 3 synthase cDNA express Gal␣1,3Gal epitopes on their cell surface that are reactive with the lectin G. simplicifolia lectin I-B 4 (Fig. 3) . However, only 5% of CHO cells transfected with murine ␣1,3-galactosyltransferase cDNA express GSL with terminal GalNAc as determined with the SMLDN1.1 mAb ϮPPPP, whereas 70% of CHO cells transfected with iGb 3 synthase cDNA are reactive with the mAb (Fig. 3) . This suggests that CHO cells transfected with ␣1,3GalT cDNA preferentially synthesize Gal␣1,3Gal on glycoprotein substrates, most likely using the preferred acceptor Gal␤1,4GlcNAc␤1-R (16). In contrast, CHO cells transfected with iGb 3 synthase cDNA synthesize Gal␣1,3Gal on GSL, primarily LacCer (Gal␤1,4Glc␤1Cer) (see Fig. 5 below), producing iGb 3 that is subsequently converted to iGb 4 (35) (Fig. 4, lane 2) . Cells can incorporate [ 3 H]GlcNAc into GlcNAc-, GalNAc-, and sialic acid-containing glycans. Glycolipids were extracted, isolated over a Sep-Pak C 18 column, and separated by TLC. The resulting autoradiographs show a small amount of material migrating as a doublet at the position of Gb 4 and a large amount of material migrating as a doublet at the position of Gb 5 produced by CHO cells transfected with iGb 3 synthase cDNA (Fig. 4, lane 1) . This labeled GSL extract was purified on a Sep-Pak C 18 cartridge and separated by HPLC using an Iatrobead column. Fractions containing each of the four major peaks were pooled and reanalyzed by TLC. The two fractions containing material that migrates with Gb 5 (Fig. 4, lanes 3 and 6) were treated with exoglycosidases. Both bands migrating at the position of Gb 5 were resistant to digestion with ␤-N-acetylhexosaminidase (Fig. 4, lanes 5 and 8) but sensitive to ␣-N-acetylgalactosaminidase (Fig. 4, lanes 4 and 7) . Following digestion with ␣-Nacetylgalactosaminidase, the two bands that had migrated at the position of Gb 5 now migrate at the position of Gb 4 . Note that the loss in the intensity of the bands following digestion reflects the loss of one of the two [ 3 H]GalNAc residues. Glycolipids often migrate as doublets by TLC, reflecting a difference in the lipid tail rather than the carbohydrate structure (17) . Digestion profiles similar to those described above were done using unlabeled glycolipids extracted from CHO cells transfected with iGb 3 synthase cDNA. Following separation on TLC, the undigested glycolipids migrating at Gb 5 and the ␣-N-acetylgalactosaminidase-digested glycolipids migrating at Gb 4 both stained with SMLDN1.1 mAb, indicating the presence of terminal GalNAc (not shown). These results show that the major isoglobo-GSL isolated from CHO cells transfected with iGb 3 synthase cDNA is iGb 5 In Vitro Activity of iGb 3 Synthase-Culture supernatant or detergent extracts from CHO cells transfected with iGb 3 synthase cDNA were assayed for activity against several GSL acceptor substrates. An increase of approximately 100-to 200-fold in galactosyltransferase activity, using LacCer as acceptor, is seen when comparing extracts from CHO cells expressing iGb 3 synthase to those expressing murine ␣1,3-galactosyltransferase or mock-transfected with vector, respectively. A faint radioactive product migrating with Gb 3 standard is seen in extracts assayed from the CHO cells expressing murine ␣1,3GalT (Fig. 5, lane 3) , but it is minor when compared with the product from CHO cells expressing iGb 3 synthase (Fig. 5,  lane 11) . Parent CHO cells express sufficient levels of endogenous LacCer to allow the detection of iGb 3 synthase activity in vitro. This accounts for the appearance of material migrating at the position of Gb 3 in all cell extracts expressing iGb 3 synthase, even in the absence of exogenous LacCer (Fig. 5, lane 9) . Neither GlcCer nor Gb 5 (not shown) are able to act as acceptor substrates. Significant, but lower activity was observed in the iGb 3 synthase transfectants when using GalCer and Gb 3 (Fig.  5, lanes 10 and 12) , which contain terminal ␤-and ␣-linked Gal, respectively. The predicted structure from the Gb 3 reaction is Gal␣1,3Gal␣1,4Gal␤1,4Glc␤1Cer, a GSL found in the rat small intestine (18) . This is also the underlying structure of (lanes 1, 3-8) or Gb 3 synthase cDNA (lane 2). Material migrating with standard Gb 4 and Gb 5 is indicated by a the brackets. The labeled GSL from iGb 3 synthase transfectants was separated by HPLC using an Iatrobead column (9) , and pooled fractions of two peaks comigrating with Gb 5 were re-run on TLC before (lanes 3 and 6) and after digestion with ␣-N-acetylgalactosaminidase (lanes 4 and 7) or ␤-Nacetylhexosaminidase (lanes 5 and 8) . The asterisk indicates G M3 , which is also produced in parent CHO cells. (Gal␣1,3Gal␣1,3Gal␣1,4Gal␤1,4Glc␤1Cer) , which is present in the cryptic cells and circular muscle of the rat small intestine (19) . The proposed structure for the product from the Gal␤1Cer reaction, Gal␣1,3Gal␤1Cer, represents a novel GSL, to the best of our knowledge. CHO cells expressing iGb 3 synthase secrete an active form of the enzyme into the culture supernatant that acts on LacCer but not on GalCer (Fig. 5, lanes 13 and 14) . Radioactive material near the origin of the TLC plates is seen in all cell extracts and is nonspecific.
CHO Cells Expressing iGb 3 Synthase Produce iGb 3 in VitroCell extracts from CHO cells expressing iGb 3 synthase show high levels of galactosyltransferase activity toward LacCer, yielding a product that migrates at the position of Gb 3 standard. Digestion of this isolated [
3 H]Gal in vitro product with specific glycosidases revealed the terminal galactose to be in an ␣1,3-linkage (Fig. 6, lane 2) . Hence, CHO cells expressing the iGb 3 synthase cDNA produce iGb 3 (Gal␣1,3Gal␤1,4Glc␤1Cer). This confirms the FACS analysis, where CHO cells transfected with iGb 3 synthase are reactive to G. simplicifolia lectin I-B 4 (a lectin that recognizes ␣1, 3-galactosyl residues) but not to anti-CD77 mAb (a monoclonal antibody that binds to Gb 3 , Gal␣1,4Gal␤Glc␤1Cer) (Fig. 3) . Similarly, total GSL extracts from CHO cells expressing iGb 3 synthase do not react with the B-subunit of Shiga toxin (35) , which specifically binds Gb 3 (20) . The globoside and Forssman structures produced in CHO transfected with iGb 3 synthase cDNA must, therefore, be synthesized on the iGb 3 glycolipid, Gal␣1,3Gal␤1,4Glc␤1Cer rather than the more common Gb 3 , Gal␣1,4Gal␤1,4Glc␤1Cer (see Fig. 8 ).
Expression of iGb 3 Synthase in Rat Tissues-RT-PCR using iGb 3 synthase-specific primers shows a widespread tissue expression of the iGb 3 synthase enzyme (Fig. 7) . Highest levels of expression are seen in the spleen, thymus, and skeletal muscle. The lung, uterus, pituitary, and heart have intermediate iGb 3 synthase expression, whereas other tissues indicate low or undetectable amounts. Similar amounts of control glyceraldehyde-3-phosphate dehydrogenase gene expression is seen in all tissues (35) . DISCUSSION We have described the cloning of a new member of the ABO gene family, iGb 3 synthase, an ␣1,3-galactosyltransferase that initiates the synthesis of isoglobo-GSL. LacCer (Gal␤1, 4Glc␤1Cer) is the preferred acceptor substrate for iGb 3 synthase, however, alternative substrates include Gal␤1Cer and, surprisingly, Gb 3 (Gal␣1,4Gal␤1,4Glc␤1Cer). This suggests that iGb 3 synthase is able to utilize multiple substrates containing a terminal Gal residue, irrespective of its anomeric configuration (Fig. 8) . Hence, iGb3 synthase may be regarded as an exception to the one-linkage-one-enzyme rule. The ability to add ␣1,3-linked Gal to these other structures may result in the appearance of novel structures in tissues depending on the available substrates. Even though iGb 3 synthase acts principally on GSL, treatment of cells expressing iGb 3 synthase with PPPP did not completely abolish the expression of Gal␣1,3Gal seen using the lectin, G. simplicifolia lectin I-B 4 (data not shown). It remains to be determined if this PPPPresistant expression of the Gal␣1,3Gal epitope is occurring on GalCer or glycoprotein acceptor substrates.
Previously cloned ␣1,3-glycosyltransferases (␣1,3GalT and Forssman or i/Gb 5 synthase) are members of the ABO gene family. They have been described in numerous mammals but are nonfunctional in Old World primates, including humans (21, 22) . These enzymes differ in their substrate specificity and may therefore have different functional significance. GSL containing the iGb 3 structure have been described in fish, rat, dog, pig, and horse (23) (24) (25) (26) (27) . At present it is not known if homologues 3 synthase RNA in rat tissues. Total RNA was isolated from rat tissues and assayed for iGb 3 synthase RNA expression using RT-PCR and gene-specific primers. Gene-specific primers for glyceraldehyde-3-phosphate dehydrogenase RNA, a housekeeping gene, produced similar levels of product in each tissue (35 of the rat iGb 3 synthase exist in other species. The phenotypic cloning procedure used to clone iGb 3 synthase has revealed that iGb 3 may be efficiently capped with GalNAc residues to form iGb 4 and iGb 5 . The presence of structures arising from iGb 3 may not be apparent in other species, because iGb 4 and iGb 5 react with many of the same immunological reagents as Gb 4 and Gb 5 , respectively. The fixative procedures used in the detection of Gal␣1,3Gal epitopes on glycoproteins may eliminate or reduce the levels of iGb 3 .
FIG. 7. Expression of iGb
Humans do not normally express the Gal␣1,3Gal epitope and as a result have high circulatory levels of the natural antiGal␣1,3Gal antibody (28) . These antibodies mediate acute rejection of xenotransplants from species that express the Gal␣1,3Gal epitope. The anomalous expression of Gal␣1,3Gal epitope in humans has been described in human cancer cells and in the thyroid from patients with the autoimmune disorder, Graves' disease (29, 30) . Furthermore, small amounts of Gal␣1,3Gal have been reported on red cells (31) . Low levels of Gal␣1,3Gal expression in humans may reflect the activity of an alternative ␣1,3-galactosyltransferase, possibly iGb 3 synthase. The accumulation of GSL containing iGb 3 structures has been noted in rat hepatomas, mammary adenocarcinomas, and tumors of colorectal origin (32) (33) (34) . Furthermore, the presence of multiple ␣1,3-galactosyltransferases may have an important clinical consequence in animals currently being assessed for xenotransplantation. Should they express the Gal␣1,3Gal epitope on both glycoproteins and glycolipids, it may be essential to eliminate these epitopes from both proteins and lipids to prevent xenotransplant rejection.
In summary, we have cloned iGb 3 synthase, an ␣1,3-galactosyltransferase, that initiates the synthesis of the isogloboseries GSL. This enzyme also has the ability to act on two further substrates found in different GSL series, the globoseries and the galactosylceramides. With the recent cloning of the Gb 3 synthase (35), gene ablation studies will be possible to determine the functional significance of different GSL series.
